Financial Performance - Record Net Sales of $49.9 million for Fiscal Year 2025, representing a growth of 15% year-over-year[1] - Fourth Quarter Net Sales of $13.3 million, an increase of 15% compared to $11.6 million in the prior year period[5] - Net Loss for FY 2025 was $3.3 million, or $0.31 per diluted share, compared to a Net Loss of $1.8 million, or $0.18 per diluted share, in the prior year[5] - The net loss for 2025 was $3,252,211, compared to a net loss of $1,820,161 in 2024, reflecting a 78.6% increase in losses[20] Sales Breakdown - E-commerce sales decreased by 6% year-over-year, contributing 48% of total Net Sales in Q4 2025[5] - Wholesale sales increased by 44% year-over-year, contributing 52% of total Net Sales in Q4 2025[5] - Net sales for the year ended December 31, 2025, increased to $49,889,286, up 15.0% from $43,295,137 in 2024[20] Profitability Metrics - Gross Margin for FY 2025 was 37.9%, down from 40.9% in the prior year, primarily due to increased product costs[5] - Gross profit for 2025 was $18,910,584, representing a gross margin of 37.9%, compared to $17,687,581 and a gross margin of 40.8% in 2024[20] - Adjusted EBITDA improved to $0.3 million in FY 2025, compared to a loss of $0.7 million in the prior year[6] - Adjusted EBITDA for the year ended December 31, 2025, was $317,091, compared to a loss of $699,362 in 2024[28] Operating Expenses and Cash Flow - Total operating expenses rose to $22,324,684, an increase of 12.3% from $19,860,673 in 2024[20] - Cash used in operating activities was $2.8 million for FY 2025, a significant change from cash provided by operating activities of $0.9 million in FY 2024[10] - Cash and cash equivalents at the end of the period decreased to $5,320,600 from $8,514,152 in 2024, a decline of 37.5%[24] Balance Sheet Items - Accounts receivable increased to $3,899,205 in 2025, up 109.4% from $1,762,911 in 2024[24] - Inventory levels rose to $7,782,169, a 30.2% increase from $5,975,676 in 2024[24] - Total liabilities increased to $7,755,050, up 28.0% from $6,062,135 in 2024[24] Strategic Initiatives - The acquisition of Navitas Organics for $38.5 million is expected to enhance Laird Superfood's product offerings and market reach[12] - The company incurred acquisition costs related to the acquisition of Navitas Organics, impacting financial performance in 2025[28] - For FY 2026, the company expects Net Sales growth of at least in the high single digits compared to FY 2025[11]

Product Development and Clinical Trials - GT-02287, the lead product candidate for treating Parkinson's disease, is currently in a Phase 1b study with a focus on safety and tolerability, involving 15-20 participants with or without a GBA1 mutation[16]. - In a Phase 1 clinical trial, 72 healthy volunteers were enrolled, with no serious adverse events reported, and a 53% increase in GCase activity observed in subjects receiving the highest dose of 13.5 mg/kg[14][15]. - The Phase 1b study's Part 1 was completed in November 2025, with Part 2 expected to conclude in Q3 2026, followed by a planned Phase 2 study in the second half of 2026[16]. - GT-02287, the lead product candidate, has shown a dose-dependent increase in GCase activity and a reduction in glucosylceramide and glucosylsphingosine levels in patient-derived cells[48]. - In animal models, GT-02287 demonstrated statistically significant improvements in GCase activity and neuroinflammation markers, along with increased survival of dopaminergic neurons[50]. - As of December 31, 2025, two clinical studies of GT-02287 have been completed, with a Phase 1b study ongoing that includes 21 patients enrolled[52][54]. - The company has commenced its first Phase 1 clinical trial but has not yet successfully completed any clinical trials or conducted sales and marketing activities necessary for commercialization[186]. - The company must demonstrate safety and efficacy through clinical trials to seek regulatory approvals for commercial sale[211]. Regulatory Environment and Compliance - The FDA requires substantial time and financial resources for obtaining regulatory approvals, which includes extensive non-clinical studies and clinical trials[74]. - The NDA submission process includes proof of safety and efficacy, with the FDA targeting ten months for initial review of a new molecular entity NDA[92]. - Clinical trials are conducted in three phases, with Phase 3 trials involving expanded patient populations to establish the overall risk/benefit ratio[84]. - The FDA must make a decision on accepting an NDA for filing within 60 days of receipt, which could include a refusal to file[91]. - The company must navigate various regulatory requirements to ensure compliance with federal, state, and local laws, which could impact product development and commercialization[75]. - The FDA may require a Risk Evaluation and Mitigation Strategy (REMS) program to ensure that the benefits of a drug outweigh its risks, which could include various safety measures[95]. - The FDA's Priority Review designation requires a review of applications within six months, compared to ten months for standard reviews, for drugs that significantly improve safety or effectiveness[106]. - Accelerated Approval allows drugs to be approved based on surrogate endpoints that predict clinical benefit, contingent on post-approval studies to verify the product's clinical benefit[107]. - The FDA may impose post-approval requirements, including Phase 4 clinical trials, to monitor a product's safety and effectiveness after commercialization[115]. - The company must comply with federal transparency laws, including the Physician Payment Sunshine Act, which requires tracking and disclosing payments to U.S. physicians[129]. - The company is subject to numerous data privacy and security obligations, including compliance with the California Consumer Privacy Act and the EU General Data Protection Regulation[135]. - The company must ensure compliance with state laws governing the privacy and security of health information, which can complicate compliance efforts[136]. Market and Financial Considerations - The company has a history of operating losses and expects to incur losses for the foreseeable future, raising substantial doubt about its ability to continue as a going concern[180]. - The company has not generated any significant revenues to date and does not expect to generate revenues from the commercial sale of products in the foreseeable future[185]. - The company plans to raise additional capital primarily through public and/or private equity financings and/or convertible debt financings, but such financing may not be available on acceptable terms[181]. - The company expects substantial additional operating expenses over the next several years as research, development, and clinical trial activities increase[184]. - The total addressable market opportunity for the company's product candidates depends on final approved product labeling, market acceptance, and patient access[207]. - Market acceptance of approved products is heavily dependent on reimbursement availability from third-party payors, which often rely on Medicare coverage policies[139]. - Global and macroeconomic conditions, including inflation and supply chain disruptions, could adversely affect the company's revenue and financial condition[190]. Intellectual Property and Licensing - The company has entered into a license agreement with Minoryx Therapeutics, obtaining exclusive worldwide rights to use its intellectual property for drug discovery[61]. - Under the Minoryx License Agreement, the company will pay royalties ranging from a high single digit to low single digit percentage of net revenues for products developed using the licensed IP[62]. - As of February 2026, the patent portfolio includes two patent families granted in the U.S., Europe, and Japan, four international PCT applications in national phase, and a provisional application to be published in 2026[66]. - The computational drug discovery platform Magellan™ has in-licensed a European patent expected to expire in 2032, related to binding site and binding energy determination[67]. - The GLB program has in-licensed a patent family in the U.S., Europe, and Japan, with expected expiration in 2037, covering composition of matter[68]. - The GBA program has also in-licensed a patent family in the U.S., Europe, and Japan, with expected expiration in 2037, covering composition of matter[69]. Risks and Challenges - The company faces risks related to market acceptance of its product candidates and competition from existing and new products[190]. - The company relies on a license to use technology that is material to its business, and any termination of this agreement could halt its ability to market products[180]. - Delays in preclinical studies and clinical trials could significantly increase product development costs and delay commercialization[198]. - The inability to enroll a sufficient number of patients in clinical trials may result in significant delays and increased development costs[206]. - The company relies on third parties for conducting clinical trials, which may lead to less control over timing and execution[201]. - Challenges in patient enrollment may arise from factors such as disease prevalence and the nature of the clinical test[203]. - Success in early preclinical studies does not guarantee similar results in later trials, necessitating adequate and well-controlled clinical trials[211].

Financial Performance - Total revenues for 2025 were $4,858,000, a decrease of 3.1% from $5,045,000 in 2024[4] - Net loss attributable to common stockholders for 2025 was $2,339,000, compared to a loss of $7,038,000 in 2024, representing a 66.8% improvement[4] - The company recognized a gain on the sale of intangible assets of $750,000 in 2025, compared to $4,000,000 in 2024[6] - Net cash used in operating activities was $4,739,000 in 2025, an improvement from $9,627,000 in 2024[6] Expenses and Liabilities - Operating expenses increased to $7,358,000 in 2025, up from $8,693,000 in 2024, primarily due to higher cost of revenues[4] - Total liabilities decreased to $2,406,000 in 2025 from $7,294,000 in 2024, a decline of 67.0%[2] Assets and Cash Position - Cash and cash equivalents decreased to $259,000 at the end of 2025 from $4,242,000 at the end of 2024, a decline of 93.9%[2] - Total assets decreased to $6,546,000 in 2025 from $13,517,000 in 2024, a reduction of 51.6%[2] Credit Loss and Shares - The company reported a credit loss of $4,745,000 in 2025, compared to no credit loss in 2024[4] - The weighted-average number of shares used in per share calculations increased to 1,368,057 in 2025 from 1,363,303 in 2024[4]

Financial Information - Kyverna Therapeutics, Inc. announced preliminary financial information for the year ended December 31, 2025, which is unaudited and subject to adjustments[6]. - The financial information provided is based on the company's current expectations and may be adjusted following year-end closing procedures[6]. Executive Appointment - Christi Shaw was appointed as Executive Chairperson of the Board, effective January 12, 2026[8]. - Ms. Shaw's initial annualized salary is set at $400,000, with additional equity awards including options for 185,000 shares and restricted stock units for 30,000 shares, both vesting over four years[10]. - If a "Change in Control" occurs during Ms. Shaw's employment, she will receive full acceleration of vesting for all unvested equity awards[12]. Corporate Information - The company is classified as an emerging growth company under the Securities Act of 1933[5]. - The press release detailing the corporate update and strategic priorities for 2026 was issued on January 12, 2026[6]. - The company is headquartered in Emeryville, California, with a principal executive office located at 5980 Horton St., Suite 550[2]. - The company trades on The Nasdaq Stock Market under the symbol KYTX[5]. Equity Awards - The performance restricted stock units (PRSUs) will vest upon the company's common stock reaching certain price targets, with a value of $200,000 divided by the per share Fair Market Value at the date of grant[10].

Financial Performance - SpyGlass Pharma successfully completed its Initial Public Offering (IPO) in February 2026, raising approximately $172.5 million[5]. - The company reported a net loss of $12.6 million, or ($5.72) per share, for Q4 2025, compared to a net loss of $8.4 million, or ($4.58) per share, for Q4 2024[15]. - Total assets increased to $115.866 billion as of December 31, 2025, compared to $23.318 billion in 2024[25]. - Current assets rose significantly to $108.768 billion in 2025 from $17.406 billion in 2024[25]. - Cash and cash equivalents reached $96.358 billion, a substantial increase from $16.268 billion in the previous year[25]. - Total liabilities decreased to $10.166 billion in 2025 from $11.246 billion in 2024[25]. - Total stockholders' deficit widened to $(98.837) billion in 2025 from $(60.474) billion in 2024[25]. - Common stock additional paid-in capital increased to $5.893 billion in 2025 from $4.387 billion in 2024[25]. - Accounts payable rose to $2.696 billion in 2025, up from $1.978 billion in 2024[25]. - Payroll-related accruals increased to $2.182 billion in 2025 from $1.282 billion in 2024[25]. - Other current liabilities surged to $3.706 billion in 2025 compared to $672 million in 2024[25]. - The aggregate liquidation preference for redeemable convertible preferred stock increased to $200.878 billion in 2025 from $73.542 billion in 2024[25]. Research and Development - Research and Development expenses increased to $7.7 million for Q4 2025, up from $5.7 million in Q4 2024, driven by the hiring of clinical personnel and the initiation of Phase 3 trials[12]. - The BIM-IOL System demonstrated a 34% and 42% reduction in mean intraocular pressure (IOP) for high and low dose groups, respectively, compared to a 35% reduction in the control group[4]. - 98% of evaluable patients in the 78-mcg dose group and 96% in the 39-mcg dose group were free from all topical IOP-lowering medications 12 months post-surgery[4]. - Phase 3 trials for the BIM-IOL System are ongoing, with full enrollment expected in 2027[5]. - The company anticipates presenting additional Phase 1/2 trial results at a future medical meeting[6]. - The BIM-IOL System showed a favorable safety profile with no serious ocular adverse events reported[6]. - SpyGlass Pharma plans to initiate a first-in-human trial for the Bimatoprost Drug Ring System (BIM-DRS) in the second half of 2026[20].

Membership and Revenue - At-risk membership was approximately 115,000, a decrease of approximately 9% compared to the same quarter prior year[5]. - Total revenue for Q4 2025 was $384.8 million, up from $370.7 million in the prior year quarter, with capitated revenue PMPM improving 9% year-over-year to $1,060[5]. - Full-year 2025 total revenue was $1.46 billion, down from $1.50 billion in the prior year, with capitated revenue PMPM improving 5% year-over-year to $1,026[5]. - For 2026, the company projects at-risk members to be between 107,000 and 117,000, with total revenues expected to range from $1.5 billion to $1.7 billion[7]. - Capitated revenue for the year ended December 31, 2025, was $1.429 billion, down from $1.484 billion in 2024, reflecting a decrease of 3.7%[27]. Financial Performance - Medical margin for Q4 2025 was negative $28.7 million, or negative $83 PMPM, compared to a positive margin of $7.3 million, or $19 PMPM in the prior year quarter[5]. - Adjusted EBITDA loss for Q4 2025 was $76.1 million, compared to a loss of $67.6 million in the same quarter prior year[5]. - The company reported a net loss of $165.7 million in Q4 2025, compared to a net loss of $129.1 million in the fourth quarter of the prior year[5]. - Normalized Adjusted EBITDA loss for full-year 2025 was $149.1 million, a $43.9 million year-over-year improvement compared to $193.0 million in 2024[5]. - The net loss for the year ended December 31, 2025, was $323,086, compared to a net loss of $310,378 in 2024, representing an increase of 4.5%[22]. - Net loss for Q4 2025 was $165.714 million, compared to a loss of $129.148 million in Q4 2024, representing an increase of 28.3% year-over-year[24]. - Adjusted EBITDA loss for Q4 2025 was $76.065 million, compared to a loss of $67.582 million in Q4 2024, indicating a deterioration of 12.3% year-over-year[24]. Operating Expenses - Total operating revenue for the year ended December 31, 2025, was $1,459,080, a decrease of 2.8% from $1,500,455 in 2024[20]. - Total operating expenses for the year ended December 31, 2025, were $1,729,381, a decrease of 5.0% compared to $1,821,113 in 2024[20]. - Total operating expense for Q4 2025 was $538.680 million, compared to $509.189 million in Q4 2024, marking an increase of 5.7% year-over-year[31]. - Adjusted operating expense for the year ended December 31, 2025, was $101.778 million, down from $111.880 million in 2024, representing a decrease of 9.7%[31]. Assets and Liabilities - Cash and restricted cash at the end of the year was $25,807, down from $44,102 at the end of 2024, a decrease of 41.5%[22]. - Total assets decreased to $656,641 as of December 31, 2025, from $783,420 in 2024, a decline of 16.2%[16]. - Total liabilities increased to $796,876 as of December 31, 2025, compared to $633,891 in 2024, an increase of 25.8%[16]. - The company incurred interest expense of $55,034 for the year ended December 31, 2025, compared to $22,173 in 2024, an increase of 148.5%[20]. Future Projections - The company expects Adjusted EBITDA for 2026 to be in the range of negative $20 million to positive $40 million, with a midpoint of $10 million, indicating approximately $170 million in year-over-year improvement[6]. - Medical margin for 2026 is projected to be between $160 million and $200 million, with PMPM ranging from $120 to $150[7]. Claims and Reserves - Medical claims expense for the year ended December 31, 2025, was $1.405 billion, slightly up from $1.398 billion in 2024, showing an increase of 0.5%[27]. - Premium deficiency reserve for Q4 2025 was $55.414 million, up from $37.927 million in Q4 2024, representing a significant increase of 46%[31]. Equity and Compensation - Equity-based compensation for the year ended December 31, 2025, was $5.581 million, slightly down from $5.752 million in 2024, reflecting a decrease of 3%[31].

Alzheimer's Disease Overview - Alzheimer's disease currently affects approximately 7 million people in the U.S. and 55 million worldwide, with projected growth to 13 million by 2050[23]. Clinical Trials and Results - The Phase 1 INTERCEPT-AD clinical trial of sabirnetug enrolled 65 participants, with 62 receiving at least one dose, demonstrating a 10.4% overall rate of ARIA-E[25][26]. - The Phase 2 ALTITUDE-AD trial will evaluate sabirnetug with a total of 542 participants, using the Integrated Alzheimer's Disease Rating Scale at 18 months as the primary outcome measure[35]. - Top-line results for the ALTITUDE-AD trial are expected to be announced in late 2026[34]. - The trial established clinical proof of mechanism for sabirnetug in early AD patients, supporting further clinical development[52]. - The most common treatment-emergent adverse events in the INTERCEPT-AD clinical trial were ARIA-E (10.4%), ARIA-H (8.3%), COVID-19 (6.3%), and hypersensitivity (6.3%)[212]. - The overall rate of ARIA-E was 10.4%, including one case of symptomatic ARIA-E (2.1%)[212]. - Delays in patient enrollment and retention in clinical trials could significantly impact the timing of necessary regulatory approvals[217]. - Throughout 2022, the company experienced delays in clinical site initiation and patient enrollment primarily due to the COVID-19 pandemic[218]. - Increased development costs were incurred in the INTERCEPT-AD clinical trial due to enrollment delays, including costs related to initiating additional trial sites[221]. - The company may face challenges in maintaining patient enrollment in clinical trials, which could affect trial outcomes[222]. Safety and Efficacy - Sabirnetug showed a dose-dependent incidence of ARIA-E: 7% for 10 mg/kg or 25 mg/kg and 21% for 60 mg/kg[26]. - Sabirnetug demonstrated a statistically significant reduction in amyloid plaque load (p=0.01) after 6-12 weeks at doses of 60 mg/kg Q4W and 25 mg/kg Q2W[53]. - Statistically significant improvements in CSF biomarkers p-tau181 (p=0.049) and neurogranin (p=0.037) were observed at the 60 mg/kg Q4W dose compared to placebo[62]. - Sabirnetug's safety profile is favorable compared to other treatments, with a lower incidence of adverse effects observed in clinical studies[93]. - The Phase 1 trial for subcutaneous administration of sabirnetug showed mild adverse events with no significant safety issues identified[27]. Product Development and Regulatory Pathway - The company plans to target an IND for the Enhanced Brain Delivery therapy by mid-2027, following promising preclinical data[27]. - The FDA granted Fast Track designation to ACU193 in October 2022, indicating potential for expedited development[65]. - The FDA review process for biologics includes a 60-day initial review period, with standard applications typically reviewed within 10 months and priority reviews within 6 months[132]. - The company must submit annual reports and safety reports to the FDA during the IND process, ensuring compliance with regulatory requirements[127]. - Clinical trials for biologics are conducted in three phases, with Phase 3 requiring two adequate and well-controlled trials for FDA approval[129]. - The FDA may issue an approval letter for a BLA, allowing commercial marketing of the product, or a Complete Response Letter (CRL) detailing deficiencies in the application[134]. - A product candidate may receive Fast Track designation, allowing for more frequent interactions with the FDA and potential rolling review of the BLA[138]. - Breakthrough Therapy designation may be granted if preliminary evidence shows substantial improvement over existing therapies, involving more intensive FDA interaction[139]. - Priority review designation aims for FDA action on marketing applications within six months, compared to ten months under standard review[140]. - Accelerated approval may be granted for products that provide meaningful therapeutic advantages, requiring post-marketing studies to verify clinical benefits[142]. - Orphan Drug Designation (ODD) can be granted for drugs intended to treat rare diseases, providing seven years of exclusivity upon first FDA approval[146]. - The BPCIA grants 12 years of data exclusivity for reference biological products, with biosimilar applications not allowed until four years post-licensure[151]. - Compliance with FDA regulations is ongoing, including record-keeping and reporting adverse experiences, with potential penalties for non-compliance[147]. - Changes to approved products require prior FDA review and approval, impacting the timeline for new indications or labeling claims[148]. - The FDA may withdraw approval if regulatory compliance is not maintained, leading to potential market withdrawal or product recalls[149]. Financial Overview - The company has incurred net losses of $121.3 million and $102.3 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $446.5 million as of December 31, 2025[181]. - The company has no product candidates approved for commercial sale and has never generated any revenue from product sales, indicating a high level of financial risk[181]. - As of December 31, 2025, the company had $54.0 million in cash and cash equivalents and $62.9 million in marketable securities, which are expected to fund operations into early 2027[185]. - The company anticipates continued losses as it develops sabirnetug and seeks regulatory approvals, with significant commercialization expenses expected if approvals are obtained[182]. - The company may need to raise additional funding sooner than anticipated if expenses increase or if it chooses to expand operations more rapidly than currently planned[185]. Market and Competitive Landscape - The company faces competition from several institutions developing AD therapies, including Biogen and Eisai, which have recently launched their own products[101]. - The need for additional AD treatment options is urgent, highlighting the potential market opportunity for sabirnetug if approved[98]. - The market for sabirnetug will depend on the cost of production, which is currently uncertain and could affect its commercial viability[203]. Collaborations and Licensing - A collaboration with JCR Pharmaceuticals includes potential milestone payments of up to $40 million related to development and up to $515 million related to sales, totaling up to $555 million[27]. - The company entered into a Loan Agreement with K2 HealthVentures LLC, borrowing $30.0 million in November 2023, with an option to borrow an additional $20.0 million[191]. - The Loan Agreement includes restrictive covenants that may limit the company's operational flexibility and ability to pursue beneficial business opportunities[192]. - The Lonza License Agreement includes an upfront fee of 1.0 million Swiss Francs and ongoing royalties based on net sales, with obligations expiring 10 years after the first commercial sales[108]. - The Halozyme License Agreement involves a seven-figure upfront payment and milestone payments tied to development and commercialization events for the subcutaneous formulation of sabirnetug[110]. Intellectual Property and Regulatory Compliance - The company holds an exclusive license from Merck for sabirnetug, which includes one issued U.S. patent and 18 foreign patents, projected to expire in July 2031[116]. - The company is focused on obtaining additional patent protections to enhance commercial success, including methods of use and formulation[117]. - The company relies on confidentiality agreements to protect proprietary information and intellectual property rights essential for its business operations[113]. - The company is subject to extensive regulatory requirements that may impact its product development and approval timelines[122]. Employee and Operational Insights - The company had 61 employees as of March 25, 2026, with 40 engaged in research and development and 21 in general and administrative functions[175]. - The company has good employee relations, which is crucial for retaining and incentivizing personnel through equity incentive plans[174]. - The company is incorporated in Delaware and maintains its principal executive offices in Newton, MA[176].

Financial Performance - Approximately 34.0% of Lands' End's yearly net revenue is generated in the fourth fiscal quarter, indicating significant seasonality in revenue [36]. - In Fiscal 2025, Lands' End's top 10 vendors accounted for approximately 63% of merchandise purchases, highlighting reliance on a limited number of suppliers [45]. - Net revenue from the Europe eCommerce distribution channel represented 6.8% of total net revenue in Fiscal 2025 [296]. - A 10% change in foreign currency exchange rates would result in a net revenue change of approximately $9.0 million for Fiscal 2025 [296]. - Foreign currency translation gains, net, for Fiscal 2025 totaled approximately $0.1 million related to international subsidiaries in the United Kingdom and Germany [296]. Business Strategy - Lands' End expects to enhance shareholder value by retiring its term loan, which will provide greater capacity for strategic capital deployment [28]. - The company plans to strategically incorporate AI technologies to optimize business processes and enhance decision-making [31]. - Lands' End aims to improve inventory efficiency and seasonal sell-through by optimizing product margins and leveraging technology solutions [42]. - The company maintains a strong digital presence and invests significantly in brand development through multi-channel marketing campaigns [50]. Workforce and Operations - Lands' End employs approximately 3,900 employees, with about 47% being part-time, reflecting a flexible workforce model [54]. - Over 95% of Lands' End's business is conducted online, with a focus on leveraging data analytics to drive personalization and improve gross margins [31]. Sustainability and Partnerships - The company is committed to sustainability initiatives, including waste reduction and efficient resource management [47]. - A joint venture with WHP Global is expected to close in the first quarter of 2026, which will hold the intellectual property associated with the Lands' End brand [39]. Financial Risks - Each one percentage point change in interest rates associated with the Term Loan Facility would result in a $2.3 million change in annual cash interest expenses [298]. - Assuming the ABL Facility was fully drawn to a principal amount of $225.0 million, each one percentage point change in interest rates would also result in a $2.3 million change in annual cash interest expenses [298]. - As of January 30, 2026, the company had $9.1 million of cash and cash equivalents denominated in foreign currency, primarily in British pound sterling, euro, and Hong Kong dollar [297].

Company Classification and Market Position - The company is classified as a "smaller reporting company" with a market value of common stock held by non-affiliates below $250 million[51]. - The Company serves a diverse customer base, with one customer accounting for 42.86% of total revenue as of December 31, 2025[104]. - The Company plans to trade on a national exchange to improve access to capital resources and broaden its customer base[96]. Product Development and Innovation - The AGMDC division has released over 125 new MMIC chip technology products since its inception, indicating strong product development[53]. - The company is actively developing a new product line of Open Radio Units for Sub 6GHz, certified to meet all ORAN KPI requirements[56]. - The Massive MIMO, 64T64R ORAN, CAT B Radio Network is expected to become the company's flagship product, providing true 5G speeds and enhanced coverage[75]. - The company offers a new line of low noise amplifiers featuring proprietary MMIC technology, covering frequency ranges from 2.0 to 18 GHz[67]. - The Company is focused on developing innovative, high-performance products to maintain and increase market share[95]. Research and Development - Research and development costs for the years ended December 31, 2025 and 2024 were $2,687,176 and $3,590,695, respectively, reflecting investment in emerging technologies[81]. - The company currently holds four patents and plans to file additional patents to protect its intellectual property[109]. - The company has received three patents from the United States Patent and Trademark Office, enhancing its intellectual property portfolio[80]. Manufacturing and Operations - The company relocated its manufacturing facility to Hauppauge, New York, which more than triples its capacity and allows for further expansion[91]. - The company’s strategy includes leveraging its established supply chain and internal capacity to process small and large orders efficiently[91]. Competition and Market Challenges - The company faces competition from established players with greater resources, emphasizing the need for innovation and cost-effective solutions[88]. - The Company is subject to extensive environmental regulations, which impose significant compliance burdens but has not adversely affected its financial statements[106][107]. Partnerships and Certifications - The Company announced a partnership with NGK Electronic Devices to become their US distributor for RF Microwave products, marking NGK's first distribution agreement with a US partner[93]. - The Company is ISO 9001:2015 and AS9120B certified for the distribution of semiconductor materials, ensuring compliance with various regulations[94]. Financial Overview - Supplier A accounted for 58.28% of materials purchased, with total material costs for fiscal year ended December 31, 2025, amounting to $17,496,944[98]. - As of March 19, 2026, the Company has 46 full-time employees and 1 part-time employee, with potential for additional contract hires[110]. - The Company maintains dynamic websites and has updated its e-commerce dashboard to enhance online sales capabilities[103].

Financial Performance - Net sales for the year ended December 31, 2025, were $118,365, a decrease of $9,768 or 7.6% compared to $128,133 in 2024[130] - The Medical Device segment saw a decrease in net sales of $2,706 or 7.8%, while Medical Imaging increased by $2,507 or 6.7%[133] - Gross profit increased to $18,006 in 2025, with a gross margin percentage of 15.2%, up from 13.1% in 2024[134] - Operating income for 2025 was $975, representing 0.8% of net sales, compared to an operating loss of $195 in 2024[139] - Cash flows provided by operating activities were $2,743 in 2025, compared to cash used of $2,250 in 2024[149] Order Backlog and Inventory - The total order backlog as of December 31, 2025, was $77,343, a 17.4% increase from $65,852 in 2024[131] - As of December 31, 2025, the company recorded a contract asset of $15,184 for unbilled customer net sales included in net sales[155] - The company had an inventory reserve of $1,853 as of December 31, 2025, reflecting evaluations of slow-moving, excess, or obsolete inventory[157] Expenses and Charges - Interest expense increased to $964 in 2025 from $744 in 2024 due to higher borrowings and interest rates[140] - Restructuring charges decreased to $266 in 2025 from $571 in 2024, reflecting cost management efforts[138] - General and administrative expenses decreased by $919 or 7.8% in 2025 due to lower incentive compensation accruals[137] Financing Activities - The company entered into a new Credit and Security Agreement with Associated Bank, providing a revolving credit facility of up to $15.0 million[145] - Net cash used in financing activities in 2025 was $1,867, primarily due to net payments on the line of credit[151] - Cash provided by financing activities in 2024 amounted to $2,765, mainly from net proceeds of $2,849 from the line of credit and $345 from notes payable[151] Tax and Equity - The reserve for uncertain tax positions aggregated $110 as of December 31, 2025, indicating potential challenges from tax authorities[159] - The company concluded that it was more likely than not that it would realize its recorded net deferred tax assets during 2025 and 2024[158] - The company's common stock was trading at a value less than its net equity value as of December 31, 2025, but no long-lived asset impairment was required[156] Estimates and Forward-Looking Statements - The majority of net sales are recognized over time, including goods produced under contract manufacturing agreements[155] - The company evaluates its estimates and assumptions regularly, which could impact financial results if they vary substantially[153] - Forward-looking statements in the annual report are based on assumptions that may prove to be inaccurate, highlighting risks and uncertainties[162]